GlassScriptPhysician profile
Jennifer Schofield
NPI 1235727264
$2,999.46
in general payments reported to CMS, 2019-2025
30 companies · $66.23 in 2025
The $66.23 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $517 · 2022: $1,166 · 2023: $721 · 2024: $529 · 2025: $66.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $802.39 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $542.33 | 2021-2024 | Farxiga |
| Novo Nordisk INC | $239.19 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Ironwood Pharmaceuticals, INC | $165.04 | 2021-2023 | Linzess |
| Pfizer INC. | $155.43 | 2021-2024 | |
| Glaxosmithkline, LLC. | $97.03 | 2024-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Novartis Pharmaceuticals Corporation | $82.74 | 2022-2023 | |
| Grifols USA, LLC | $80.83 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.28 | 2022-2023 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $67.17 | 2023 | Rexulti, Abilify Maintena |
| Paratek Pharmaceuticals, INC. | $66.09 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $63.46 | 2023 | Xarelto |
| Amgen INC. | $61.70 | 2022-2024 | Otezla, Repatha |
| Lilly USA, LLC | $61.61 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Collegium Pharmaceutical, INC. | $52.59 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.41 | 2022-2023 | Jardiance |
| Exact Sciences Corporation | $44.91 | 2024 | Cologuard Collection Kit |
| Uswm, LLC | $33.48 | 2021 | |
| Organon LLC | $32.09 | 2024 | |
| Agile Therapeutics, INC. | $29.57 | 2021 | |
| Idorsia Pharmaceuticals US INC | $29.01 | 2023 | Quviviq |
| Insulet Corporation | $27.04 | 2023 | Omnipod |
| Sanofi Pasteur INC. | $20.69 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.54 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.72 | 2024 | Voquezna |
| Eisai INC. | $19.26 | 2024 | |
| Merck Sharp & Dohme LLC | $17.92 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Nestle Healthcare Nutrition INC. | $17.22 | 2022 | |
| G Medical Diagnostic Services, INC. | $14.54 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.18 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Schofield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.